NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Zymeworks Inc. (ZYME) Stock Analysis

Zymeworks Inc. (ZYME) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ZYME

$29.19

−$0.71 (−2.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZYME with… →

ZYME Key Statistics

As of Sep 4, 2026
Trading
Open
$29.81
Previous Close
$29.90
Day's Range
29.09–29.99
52-Week Range
14.69–31.34
Volume
476.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$2.09B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
25.02
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
56.22
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.02
Financials (FY)
Revenue (FY)
$105.97M+38.87%
Net Income (FY)
−$81.13M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
70.96M
1-Year Return
+107.32%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
620.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ZYME Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.86%
2025+79.85%
2024+40.90%
2023+32.19%
2022−52.04%
2021−65.32%
2020+3.96%
2019+209.67%
2018+93.34%
2017 (partial year)−41.59%

As of September 4, 2026.

ZYME Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$105.97M−$81.13M−76.6%
2024$76.30M−$122.70M−160.8%
2023$76.01M−$118.67M−156.1%
2022$412.48M$124.34M30.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$105.97M—−$92.54M−$81.13M−76.6%
2024$76.30M—−$119.82M−$122.70M−160.8%
2023$76.01M—−$138.01M−$118.67M−156.1%
2022$412.48M—$130.49M$124.34M30.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZYME Valuation vs Biotechnology Median

Median of 656 stocks
MetricZYMEBiotechnology medianvs median
P/S ratio56.2215.263.7x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Zymeworks Inc. (ZYME) at $2.09B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 231 employees.

Over the past 52 weeks the price has ranged from $14.69 to $31.34. The most recent close on file for ZYME is $29.19, dated September 4, 2026. That is −$0.71 (−2.37%) against the previous close. The latest close sits 98.71% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $105.97M. That is +38.87% against the prior fiscal year, when revenue was $76.30M. The same year closed with a net loss of $81.13M. The reported profit margin is 0%. Trailing earnings per share are −2.02.

Across the 4 fiscal years on file, revenue moves from $412.48M in 2022 to $105.97M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 25.02. Measured against sales, the shares trade at 56.22 times revenue. On price-to-sales that is 3.7 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +107.32%. Across 5 years the annualized return works out at −2.11%. The reported beta is 1.19. Daily returns over the trailing 9 years annualize to a volatility of 61.19%.

Growth & Income

The record shows no dividend for ZYME.

2026 is still running; the price is +10.86% year to date. Across the complete calendar years on file, 2019 returned +209.67% and 2021 returned −65.32%. Of the 8 complete calendar years on file, 6 finished higher.

Peer Comparison

Zymeworks Inc. (ZYME) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zymeworks Inc. ZYME $2.09B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Zymeworks Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Zymeworks Inc.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Visit website →